Callan Family Office LLC bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 7,470 shares of the biotechnology company's stock, valued at approximately $491,000.
Several other large investors have also made changes to their positions in the company. E Fund Management Co. Ltd. boosted its position in BioMarin Pharmaceutical by 13.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 14,462 shares of the biotechnology company's stock valued at $951,000 after buying an additional 1,666 shares in the last quarter. Candriam S.C.A. raised its position in BioMarin Pharmaceutical by 77.2% in the 4th quarter. Candriam S.C.A. now owns 580,222 shares of the biotechnology company's stock valued at $38,138,000 after purchasing an additional 252,820 shares during the last quarter. Inceptionr LLC acquired a new position in BioMarin Pharmaceutical in the fourth quarter worth $2,236,000. Arizona State Retirement System grew its holdings in shares of BioMarin Pharmaceutical by 1.6% during the fourth quarter. Arizona State Retirement System now owns 55,280 shares of the biotechnology company's stock worth $3,634,000 after purchasing an additional 880 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth $920,000. Institutional investors own 98.71% of the company's stock.
BioMarin Pharmaceutical Stock Up 0.1 %
NASDAQ BMRN traded up $0.06 on Thursday, reaching $70.60. The company had a trading volume of 931,876 shares, compared to its average volume of 1,773,692. The company's fifty day moving average is $66.08 and its 200-day moving average is $69.09. The firm has a market capitalization of $13.47 billion, a price-to-earnings ratio of 32.09, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. BioMarin Pharmaceutical Inc. has a 1-year low of $60.63 and a 1-year high of $94.85.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. On average, research analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, CAO Erin Burkhart sold 1,344 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $68.38, for a total transaction of $91,902.72. Following the completion of the transaction, the chief accounting officer now owns 13,105 shares in the company, valued at approximately $896,119.90. This represents a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.85% of the company's stock.
Analyst Ratings Changes
Several research analysts recently issued reports on BMRN shares. Oppenheimer upgraded shares of BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 price target on the stock in a research report on Monday, February 24th. Citigroup upped their target price on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $90.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. StockNews.com upgraded shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Monday. Finally, Wedbush reiterated an "outperform" rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $94.00.
Check Out Our Latest Report on BioMarin Pharmaceutical
BioMarin Pharmaceutical Company Profile
(
Free Report)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Articles
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
